Literature DB >> 24333775

Botulinum toxin B in the sensory afferent: transmitter release, spinal activation, and pain behavior.

Marc J Marino1, Tetsuji Terashima2, Joanne J Steinauer1, Kelly A Eddinger1, Tony L Yaksh1, Qinghao Xu3.   

Abstract

We addressed the hypothesis that intraplantar botulinum toxin B (rimabotulinumtoxin B: BoNT-B) has an early local effect upon peripheral afferent terminal releasing function and, over time, will be transported to the central terminals of the primary afferent. Once in the terminals it will cleave synaptic protein, block spinal afferent transmitter release, and thereby prevent spinal nociceptive excitation and behavior. In mice, C57Bl/6 males, intraplantar BoNT-B (1 U) given unilaterally into the hind paw had no effect upon survival or motor function, but ipsilaterally decreased: (1) intraplantar formalin-evoked flinching; (2) intraplantar capsaicin-evoked plasma extravasation in the hind paw measured by Evans blue in the paw; (3) intraplantar formalin-evoked dorsal horn substance P (SP) release (neurokinin 1 [NK1] receptor internalization); (4) intraplantar formalin-evoked dorsal horn neuronal activation (c-fos); (5) ipsilateral dorsal root ganglion (DRG) vesicle-associated membrane protein (VAMP); (6) ipsilateral SP release otherwise evoked bilaterally by intrathecal capsaicin; (7) ipsilateral activation of c-fos otherwise evoked bilaterally by intrathecal SP. These results indicate that BoNT-B, after unilateral intraplantar delivery, is taken up by the peripheral terminal, is locally active (blocking plasma extravasation), is transported to the ipsilateral DRG to cleave VAMP, and is acting presynaptically to block release from the spinal peptidergic terminal. The observations following intrathecal SP offer evidence for a possible transsynaptic effect of intraplantar BoNT. These results provide robust evidence that peripheral BoNT-B can alter peripheral and central terminal release from a nociceptor and attenuate downstream nociceptive processing via a presynaptic effect, with further evidence suggesting a possible postsynaptic effect. Published by Elsevier B.V.

Entities:  

Keywords:  Botulinum toxin; Dorsal root ganglion; Neurotransmitter release; Sensory afferent; Spinal cord; Substance P; VAMP

Mesh:

Substances:

Year:  2013        PMID: 24333775      PMCID: PMC3960322          DOI: 10.1016/j.pain.2013.12.009

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  108 in total

Review 1.  Molecular mechanisms of nociception.

Authors:  D Julius; A I Basbaum
Journal:  Nature       Date:  2001-09-13       Impact factor: 49.962

2.  Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor.

Authors:  P W Mantyh; S D Rogers; P Honore; B J Allen; J R Ghilardi; J Li; R S Daughters; D A Lappi; R G Wiley; D A Simone
Journal:  Science       Date:  1997-10-10       Impact factor: 47.728

3.  Aberrant sensory responses are dependent on lesion severity after spinal cord contusion injury in mice.

Authors:  Emily L Hoschouer; Michele D Basso; Lyn B Jakeman
Journal:  Pain       Date:  2009-12-22       Impact factor: 6.961

Review 4.  Anatomy of primary afferents and projection neurones in the rat spinal dorsal horn with particular emphasis on substance P and the neurokinin 1 receptor.

Authors:  A J Todd
Journal:  Exp Physiol       Date:  2002-03       Impact factor: 2.969

5.  Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia.

Authors:  Hsu-Tang Liu; Shen-Kou Tsai; Ming-Chang Kao; Jenkin S Hu
Journal:  Pain Med       Date:  2006 Jan-Feb       Impact factor: 3.750

6.  Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin.

Authors:  P Gazerani; N S Pedersen; A M Drewes; L Arendt-Nielsen
Journal:  Br J Dermatol       Date:  2009-05-11       Impact factor: 9.302

7.  Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide.

Authors:  R Gamse; A Saria
Journal:  Eur J Pharmacol       Date:  1985-08-07       Impact factor: 4.432

8.  Spinal N-methyl-D-aspartate receptors and nociception-evoked release of primary afferent substance P.

Authors:  A Nazarian; G Gu; N G Gracias; K Wilkinson; X Y Hua; M R Vasko; T L Yaksh
Journal:  Neuroscience       Date:  2008-03-03       Impact factor: 3.590

9.  Basal and activity-induced release of substance P from primary afferent fibres in NK1 receptor knockout mice: evidence for negative feedback.

Authors:  Isobel J Lever; Andrew D Grant; Sophie Pezet; Norma P Gerard; Susan D Brain; Marzia Malcangio
Journal:  Neuropharmacology       Date:  2003-12       Impact factor: 5.250

10.  Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons.

Authors:  Laura Restani; Francesco Giribaldi; Maria Manich; Kinga Bercsenyi; Guillermo Menendez; Ornella Rossetto; Matteo Caleo; Giampietro Schiavo
Journal:  PLoS Pathog       Date:  2012-12-27       Impact factor: 6.823

View more
  19 in total

1.  Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt.

Authors:  Shafaq Sikandar; Ynette Gustavsson; Marc J Marino; Anthony H Dickenson; Tony L Yaksh; Linda S Sorkin; Roshni Ramachandran
Journal:  Eur J Neurosci       Date:  2016-05-19       Impact factor: 3.386

2.  Complexity of systems and actions underlying neurogenic inflammation.

Authors:  Tony L Yaksh; Anna Di Nardo
Journal:  Semin Immunopathol       Date:  2018-05       Impact factor: 9.623

Review 3.  [Use of intracutaneous or subcutaneous botulinum toxin for postherpetic neuralgia].

Authors:  L Halb; B J Amann; H Bornemann-Cimenti
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

Review 4.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 5.  Neurogenic inflammation and its role in migraine.

Authors:  Roshni Ramachandran
Journal:  Semin Immunopathol       Date:  2018-03-22       Impact factor: 9.623

Review 6.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

7.  Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents.

Authors:  Roshni Ramachandran; Carmen Lam; Tony L Yaksh
Journal:  Neurobiol Dis       Date:  2015-05-06       Impact factor: 5.996

Review 8.  Botulinum Toxin for Neuropathic Pain: A Review of the Literature.

Authors:  Hyun-Mi Oh; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2015-08-14       Impact factor: 4.546

Review 9.  The search for novel analgesics: targets and mechanisms.

Authors:  Tony L Yaksh; Sarah A Woller; Roshni Ramachandran; Linda S Sorkin
Journal:  F1000Prime Rep       Date:  2015-05-26

Review 10.  Current status and future directions of botulinum neurotoxins for targeting pain processing.

Authors:  Sabine Pellett; Tony L Yaksh; Roshni Ramachandran
Journal:  Toxins (Basel)       Date:  2015-11-04       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.